The cancer journal
-
Angiogenesis is critical to tumor cell growth. Vascular endothelial growth factor and its receptors play key roles in this pathway and are targets for cancer drug therapy. Blockade of the angiogenesis pathway has shown efficacy and led to improvements in survival in several tumor types. This chapter focuses on the intraveneous antiangiogenic agents approved in metastatic colorectal cancer and their role in the treatment of this disease.
-
Colorectal cancer is commonly diagnosed throughout the world, and treatment options have greatly expanded over the last 2 decades. Targeting angiogenesis has been a major focus of study in a variety of malignancy types. ⋯ Regorafenib was the first TKI to demonstrate efficacy and is an orally active inhibitor of angiogenic (including the vascular endothelial growth factor receptors 1, 2, and 3), stromal, and oncogenic receptor tyrosine kinases. There are ongoing investigations of both regorafenib and ninetanib; however, there remains a critical need to better understand novel combinations with TKIs that could prove more efficacious than available options.